Does Anthem (Elevance Health) Cover NMN or NR (Nicotinamide Mononucleotide/Riboside)?

Why Anthem Does Not Cover NMN or NR

Anthem (Elevance Health) excludes NMN and NR from every tier of its commercial PPO, HMO, and Medicare Advantage formularies because neither compound is an FDA-approved medication. Insurance formularies list drugs that carry an active New Drug Application (NDA) or Biologics License Application (BLA) with the FDA. NMN and NR have neither.

This is not a gap that prior authorization or step therapy can bridge. Anthem's pharmacy benefit managers (currently Express Scripts for most Anthem plans and, for certain carved-out groups, CVS Caremark) build formularies from the FDA's approved drug database. A compound that never entered that database has no National Drug Code (NDC) eligible for adjudication through the pharmacy benefit. Some patients confuse NMN and NR with prescription nicotinamide (niacinamide) or prescription niacin formulations like Niaspan, which have appeared on Anthem formularies in the past. Those are chemically distinct molecules with different metabolic fates [1].

The bottom line: no Anthem plan covers NMN or NR, and this is unlikely to change unless one of these compounds completes FDA approval as a prescription drug.

NMN's Complicated Regulatory Status

NMN occupies a regulatory gray zone that makes insurance coverage even less likely. In November 2022, the FDA ruled that NMN could not be marketed as a dietary supplement because it had been authorized for investigation as a new drug before it was sold as a supplement [2]. The agency cited Section 201(ff)(3)(B)(ii) of the Federal Food, Drug, and Cosmetic Act.

That ruling followed Metro International Biotech's IND filing for MIB-626, a pharmaceutical-grade NMN formulation being tested for age-related metabolic decline. The FDA's position effectively removed NMN from the supplement market. Brands that had sold NMN capsules either pulled products, reformulated, or challenged the ruling through industry groups like the Natural Products Association [3].

For Anthem members, this creates a double barrier. NMN is not an approved drug (so the pharmacy benefit won't cover it) and is no longer a recognized supplement (so the limited supplement riders some Anthem plans offer cannot apply either). Even if a physician writes a prescription for compounded NMN from a 503A or 503B pharmacy, Anthem's standard benefit design excludes compounded products unless they meet narrow exception criteria, typically reserved for medically necessary compounds with no commercially available equivalent.

NR Remains Available Over the Counter

Nicotinamide riboside has a clearer path to consumer access than NMN, though insurance still does not cover it. NR received FDA "new dietary ingredient" (NDI) notification acceptance and has been marketed as the branded supplement Tru Niagen (by ChromaDex) since 2017 [4]. The compound also received Generally Recognized as Safe (GRAS) status.

A 30-day supply of Tru Niagen (300 mg/day) costs roughly $40 to $50 at retail pharmacies and online. Higher doses increase the monthly spend. Anthem treats NR the same way it treats other dietary supplements: excluded from the pharmacy benefit. Some Anthem plans with wellness or health savings account (HSA) integration allow members to use pre-tax HSA or FSA dollars for supplements if a physician provides a letter of medical necessity, but this is an account-level tax benefit, not an insurance coverage benefit.

NR and NMN both raise intracellular NAD+ levels in human tissue, though the pharmacokinetic routes differ. NR is converted to NMN by nicotinamide riboside kinases (NRK1 and NRK2) before entering the NAD+ salvage pathway [5]. Both compounds therefore converge on the same biochemical endpoint.

What the Clinical Evidence Actually Shows

The evidence for NMN and NR in humans is early-stage. No compound in this class has completed a Phase III randomized controlled trial with a primary clinical endpoint like cardiovascular events, mortality, or disease progression.

Yoshino et al. published the first notable NMN trial in Science in 2021. The study enrolled 25 postmenopausal women with prediabetes and gave them 250 mg NMN daily for 10 weeks. NMN improved skeletal muscle insulin sensitivity by approximately 25% compared to placebo, measured by hyperinsulinemic-euglycemic clamp. The study did not show changes in body weight, blood pressure, or lipid profiles [6]. With only 25 participants, the trial was designed to detect metabolic signals, not clinical outcomes.

For NR, a 2018 trial by Martens et al. randomized 24 lean, healthy older adults to NR 500 mg twice daily or placebo for 6 weeks. NR raised NAD+ levels in peripheral blood mononuclear cells by approximately 60% and showed a trend toward lower systolic blood pressure (reduction of 5.6 mmHg in the crossover analysis), though the blood pressure finding did not reach significance in the primary parallel-group analysis [7]. A larger NR trial (n=118) by Elhassan et al. in 2019 confirmed that NR 1 to 000 mg/day increased NAD+ metabolites in skeletal muscle and reduced circulating inflammatory cytokines in older men [8].

The Interventions Testing Program (ITP) at the National Institute on Aging tested NR in mice and found no lifespan extension at the doses used [9]. That result tempered some of the enthusiasm generated by earlier rodent studies showing NR and NMN benefits in models of aging and metabolic disease.

Dr. Charles Brenner, the biochemist who discovered NR's role as an NAD+ precursor, has stated: "NAD+ precursors are not anti-aging drugs. They are vitamins that correct NAD+ deficiency in conditions of metabolic stress" [10]. That framing matters for insurance coverage because it positions NR and NMN as nutritional interventions rather than treatments for diagnosed disease.

The Cost of NMN and NR Without Insurance

Because Anthem will not cover either compound, the full cost falls on the patient. Pricing varies significantly by source, dose, and formulation.

NR is the more affordable option. Tru Niagen (the only NR product with published human trial data behind its specific formulation) costs $40 to $50 per month at 300 mg/day. Generic NR from other manufacturers ranges from $30 to $60 per month, though purity and bioavailability vary. ConsumerLab and similar third-party testing organizations have flagged that some NR supplements contain less active ingredient than labeled [4].

NMN pricing has become more volatile since the FDA's 2022 ruling. Products that remain on the market (some sold as "research compounds" rather than supplements) range from $50 to $120 per month for doses of 250 to 500 mg/day. Pharmaceutical-grade NMN from compounding pharmacies may cost more, sometimes $150 to $200 per month, and requires a physician's prescription.

Patients considering these compounds should weigh the cost against the evidence. A year of NR at 300 mg/day costs approximately $500 to $600. A year of NMN at 250 mg/day costs $600 to $1,400 depending on source. Neither expenditure is supported by outcomes data showing reduced disease incidence or mortality in humans.

Can You Appeal an Anthem Denial for NMN or NR?

There is no meaningful appeal pathway because there is no coverage determination to appeal. Anthem's appeals process under the Employee Retirement Income Security Act (ERISA) for employer-sponsored plans, or under state insurance regulations for individual and small-group plans, applies when a covered benefit is denied. NMN and NR are not covered benefits on any Anthem plan [11].

If a claim is submitted (for example, through a compounding pharmacy) and rejected, the explanation of benefits (EOB) will typically show a denial code indicating the product is "not on formulary" or "not a covered benefit." Anthem's internal appeal and the subsequent external review through a state Independent Review Organization (IRO) both require the disputed service to fall within the plan's benefit structure. An IRO reviewer evaluating a supplement claim will almost certainly uphold the denial.

The one narrow exception: if a physician argues that a compounded NMN or NR preparation is medically necessary for a specific diagnosed condition (such as a rare NAD+ biosynthesis deficiency like Leber congenital amaurosis type 9, which involves NMNAT1 mutations), and the plan covers compounded medications under its pharmacy or medical benefit, an appeal might gain traction [12]. This scenario applies to a very small number of patients with documented genetic conditions.

Alternatives That Anthem May Cover

Patients interested in NAD+ biology for metabolic health have several Anthem-covered alternatives worth discussing with their physician.

Prescription niacin (nicotinic acid) and niacinamide are older NAD+ precursors that do have clinical data behind them. Extended-release niacin (Niaspan) was widely prescribed for dyslipidemia before the AIM-HIGH trial (N=3,414) showed it did not reduce cardiovascular events when added to a statin [13]. Niacin fell out of favor for lipid management, but it remains an inexpensive, Anthem-covered NAD+ precursor at generic pricing under $15 per month.

For metabolic health specifically, GLP-1 receptor agonists like semaglutide and tirzepatide have strong Phase III data showing weight loss, glycemic improvement, and cardiovascular event reduction. Anthem covers both semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) on most formularies, though prior authorization and step therapy requirements apply. The STEP-1 trial (N=1,961) demonstrated 14.9% mean body weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo [14].

Metformin, the subject of the ongoing TAME (Targeting Aging with Metformin) trial, is another Anthem-covered medication that some longevity-focused clinicians prescribe off-label. Generic metformin costs under $10 per month and is covered on Anthem's lowest formulary tier [15].

"Rather than spending $100 per month on an unproven NAD+ precursor, patients should first optimize the metabolic interventions that have decades of safety and efficacy data behind them," says the Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy [16].

What Would Need to Change for Anthem to Cover NMN or NR

Two conditions must be met before any insurer, including Anthem, would add NMN or NR to a formulary. First, one of these compounds must complete the FDA drug approval process, including Phase III trials demonstrating safety and efficacy for a specific indication. Second, the approved product must receive a favorable pharmacoeconomic assessment that justifies formulary inclusion.

Metro International Biotech's MIB-626 (pharmaceutical NMN) has completed Phase I and Phase II trials. Published Phase I data showed that single doses up to 3 to 000 mg and repeated doses of 1 to 000 mg twice daily for 28 days were well tolerated in healthy adults [17]. Phase II data for MIB-626 in acute COVID-19 and in older adults with obesity have been presented at conferences but, as of May 2026, full peer-reviewed publications for efficacy endpoints remain limited.

If MIB-626 or a similar NMN drug candidate reaches FDA approval (likely no earlier than 2028 or 2029 based on typical development timelines), Anthem's pharmacy and therapeutics committee would evaluate it against existing metabolic therapies. The drug's pricing, comparative efficacy, and target population would determine formulary placement. Given that Anthem already covers GLP-1 agonists, SGLT2 inhibitors, and metformin for overlapping metabolic indications, a new NAD+ precursor drug would face a high bar for formulary inclusion.

Patients who want to track the regulatory progress of NMN-based drugs can monitor ClinicalTrials.gov for MIB-626 and related compounds.